Skip to main content
Amoy Diagnostics Co.,Ltd. logo

Amoy Diagnostics Co.,Ltd. — Investor Relations & Filings

Ticker · 300685 ISIN · CNE1000034D3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,089 across all filing types
Latest filing 2020-04-13 AGM Information
Country CN China
Listing Shenzhen Stock Exchange 300685

About Amoy Diagnostics Co.,Ltd.

https://www.amoydx.com

Amoy Diagnostics Co., Ltd. specializes in the development and commercialization of molecular diagnostic products for precision oncology. The company provides a comprehensive portfolio of testing kits designed to identify genetic mutations and biomarkers essential for personalized cancer treatment. Its core technology platforms include the proprietary ADx-ARMS, Super-ARMS, and specialized Next-Generation Sequencing (NGS) solutions. AmoyDx focuses on companion diagnostics (CDx), collaborating extensively with global pharmaceutical companies to integrate diagnostic testing into clinical drug development and patient management. Key products cover a wide range of solid tumors, including lung, colorectal, and breast cancers, facilitating targeted therapy selection and monitoring. The company maintains rigorous quality standards, with numerous products receiving regulatory approvals for clinical use in multiple international markets.

Recent filings

Filing Released Lang Actions
关于召开2019年度股东大会的通知
AGM Information Classification · 100% confidence The document is a detailed notice about the convening of the 2019 Annual General Meeting (AGM) of Xiamen Aide Bio-pharmaceutical Technology Co., Ltd. It includes information about the meeting date, location, agenda items, voting procedures, registration methods, and other logistical details. The document does not contain the actual annual report, financial statements, or voting results, but rather the notification and arrangements for the AGM. The presence of agenda items such as the 2019 annual report and financial statements indicates this is a meeting notice. The document length is about 5240 characters, which is consistent with a detailed meeting notice rather than a full report. Therefore, the appropriate classification is AGM Information (AGM-R).
2020-04-13 Chinese
关于终止部分募集资金投资项目并将剩余募集资金用于永久补充流动资金的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from a company regarding the termination of part of its fundraising investment projects and the reallocation of remaining raised funds to permanently supplement working capital. It details the original fundraising, usage plans, reasons for termination, approvals by the board, supervisory board, and independent directors, and includes opinions from the sponsoring institution. The document is a formal disclosure about changes in the use of previously raised capital, not a full financial report or earnings release. It is not a report publication announcement since it contains substantive content and explanations. The content fits the category of Capital/Financing Update (CAP) as it concerns updates on fundraising and capital usage.
2020-04-13 Chinese
中信证券股份有限公司关于公司2019年度内部控制自我评价报告的核查意见
Audit Report / Information Classification · 95% confidence The document is titled as an internal control self-evaluation report for the year 2019 of Xiamen Aide Biomedical Technology Co., Ltd., with verification opinions from CITIC Securities Co., Ltd. It extensively discusses the company's internal control environment, principles, systems, activities, and evaluation standards, including financial and non-financial control defect criteria. The document is detailed and contains substantive content about internal control evaluation rather than just an announcement or summary. It is not a full annual report (10-K) but a focused audit-related report on internal controls. The presence of detailed internal control evaluation and audit opinions aligns with the definition of an Audit Report / Information (AR). The document length (12,002 characters) and content confirm it is not a brief announcement or certification but a full report on internal control evaluation. Therefore, the appropriate classification is AR (Audit Report / Information). FY 2019
2020-04-13 Chinese
2020年第一季度业绩预告
Earnings Release Classification · 95% confidence The document is a quarterly earnings forecast for the first quarter of 2020 by Xiamen Aide Bio-Pharmaceutical Technology Co., Ltd. It provides estimated financial results, including revenue and net profit projections, and notes that the forecast is unaudited and preliminary. The document explicitly states it is a performance forecast for a quarterly period (January 1 to March 31, 2020) and includes financial metrics and explanations for performance changes. It is not a full interim report but a forecast announcement of quarterly earnings. Given the content and length (1206 characters), it fits the definition of an Earnings Release (ER), which is an initial announcement of quarterly financial results with key highlights only. Q1 2020
2020-04-09 Chinese
关于股东股份减持计划时间届满并拟继续减持公司股份的公告
Major Shareholding Notification Classification · 100% confidence The document is an announcement regarding a shareholder's plan to reduce their holdings in the company shares, including details about the previous reduction plan's expiration and a new plan to continue reducing shares. It includes specifics on the shareholder, reduction quantities, timing, and compliance with regulations. There is no financial statement, earnings data, or management discussion. The document is a formal disclosure about shareholding changes by a significant shareholder but does not report on financial results or corporate governance changes. This fits the category of Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels.
2020-03-24 Chinese
关于部分限制性股票回购注销完成的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the completion of repurchase and cancellation of restricted shares by the company. It details the number of shares repurchased, the price, the approval process, and the impact on share capital structure. The document is relatively short (3200 characters) and focuses on a specific corporate action related to share repurchase and cancellation. It does not contain financial statements or comprehensive financial data, nor is it a report or presentation. Therefore, it fits the category of Transaction in Own Shares (POS), which covers company buyback or sale of its own shares.
2020-03-24 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.